Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Intrathecal (IT) Administration of Rituximab to Treat Multiple Sclerosis (MS)

Posted Feb 22 2012 7:00pm

Description of Invention:
Multiple sclerosis (MS) is a chronic, neurological, autoimmune, demyelinating disease. The pathology of MS is characterized by an abnormal immune response directed against the central nervous system. In particular, T-lymphocytes are activated against the myelin sheath of the neurons of the central nervous system causing demyelination. Secondary-progressive multiple sclerosis (SP-MS) is the chronic phase of MS. The majority of people who have relapsing-remitting MS eventually develop SP-MS. There are currently no effective treatments for SP-MS patients who do not have evidence for focal brain inflammation measured by contrast enhancing lesions (CEL) on brain MRI. NIH investigators have proposed that intrathecal administration of Rituximab, a monoclonal antibody (Ab) that depletes B cells and effectively decreases CEL in relapsing-remitting MS (RR-MS) but does not affect progression of disability in progressive MS, may deplete B cells from the intrathecal compartment leading to inhibition of T cell activation within intrathecal compartment, and thereby provide a novel therapeutic approach to treat SP-MS. A Clinical trial is in progress to evaluate this novel approach.

Applications:
Improved therapeutics to treat or prevent Secondary-progressive multiple sclerosis (SP-MS).

Advantages:
This technology would provide the first effective therapy for Secondary-progressive multiple sclerosis patients lacking contrast enhancing lesions.

Development Status:
  • Clinical
  • In vivo data available (animal)


Inventors:
Bibiana Bielekova (NINDS)


Patent Status:
HHS, Reference No. E-249-2011/0
US, Application No. 61/539,870 filed 27 Sep 2011


Relevant Publication:
  1. Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe). [ ClinicalTrials.gov Identifier NCT01212094 ]



For Licensing Information Please Contact:
Suryanarayana Vepa Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vepas@mail.nih.gov
Phone: 301-435-5020
Fax: 301-402-0220


Ref No: 2377

Updated: 02/2012

Post a comment
Write a comment:

Related Searches